MARKET

AMRN

AMRN

Amarin
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.40
-0.04
-0.74%
After Hours: 5.44 +0.04 +0.74% 18:39 09/24 EDT
OPEN
5.39
PREV CLOSE
5.44
HIGH
5.52
LOW
5.33
VOLUME
2.76M
TURNOVER
--
52 WEEK HIGH
9.25
52 WEEK LOW
3.360
MARKET CAP
2.13B
P/E (TTM)
514.29
1D
5D
1M
3M
1Y
5Y
TENX: Second Quarter Results
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT
Benzinga · 1d ago
Cramer Shares His Thoughts On Dynavax, Nucor And Amarin
On CNBC's "Mad Money Lightning Round," Jim Cramer said Dynavax Technologies Corporation (NASDAQ: DVAX) is good. He loves the immuno drug stories.
Benzinga · 2d ago
Amarin Charts Are Charting a Course Toward Improvement
However, traders will need to show a lot of patience if they buy shares of the biopharmaceutical company.
TheStreet.com · 2d ago
BRIEF-Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA (Icosapent Ethyl) Growth in U.S.
reuters.com · 4d ago
Amarin Outlines New Go-To-Market Strategy To Accelerate VASCEPA Growth In US
Amarin Corporation plc (NASDAQ:AMRN) today outlined its new Go-to-Market strategy to accelerate growth of VASCEPA® (icosapent ethyl) in the United States, which focuses on expanding healthcare professional engagement
Benzinga · 4d ago
Amarin Pharmaceuticals Granted U.S. Patent Titled 'Methods of reducing the risk of cardiovascular events in a subject'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6601&f=G&l=50&d=PTXT&p=133&S1=20210914&OS=20210914&RS=20210914
Benzinga · 09/14 13:36
BRIEF-Amarin Announces First European Launch Of Vazkepa In Germany
reuters.com · 09/13 13:00
Amarin Announces First European Launch of VAZKEPA (icosapent ethyl) in Germany
Brings groundbreaking therapy to patients in Germany with residual cardiovascular risk and marks key milestone in corporate growth strategyDUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today ...
GlobeNewswire · 09/13 11:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AMRN. Analyze the recent business situations of Amarin through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMRN stock price target is 10.75 with a high estimate of 19.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 420
Institutional Holdings: 181.68M
% Owned: 46.02%
Shares Outstanding: 394.77M
TypeInstitutionsShares
Increased
58
8.64M
New
29
1.04M
Decreased
53
12.05M
Sold Out
44
9.02M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Lars Ekman
President/Chief Executive Officer/Director
Karim Mikhail
Chief Financial Officer/Senior Vice President/Assistant Secretary
Michael Kalb
Senior Vice President/Chief Scientific Officer
Stephen Ketchum
Senior Vice President
Aaron Berg
Non-Executive Independent Director
Patrick O'Sullivan
Non-Executive Independent Director
Kristine Peterson
Non-Executive Independent Director
David Stack
Non-Executive Independent Director
Jan van Heek
Non-Executive Independent Director
Joseph Zakrzewski
No Data
  • All
  • Financials
  • Insiders
More
About AMRN
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Webull offers kinds of Amarin Corporation plc (ADR) stock information, including NASDAQ:AMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMRN stock methods without spending real money on the virtual paper trading platform.